Navigation Links
MQ Associates, Inc. Announces Completion of Tender Offer and Consent Solicitation Relating to its 12 1/4% Senior Discount Notes due 2012
Date:1/31/2008

ALPHARETTA, Ga., Jan. 31 /PRNewswire/ -- MQ Associates, Inc. ("MQ Associates") announced today that it has completed its previously announced cash tender offer and consent solicitation with respect to its outstanding 12 1/4% Senior Discount Notes due 2012 (CUSIP No. 55345RAC2) (the "Notes"). The tender offer and consent solicitation expired at midnight, New York City time, on January 29, 2008 (the "Expiration Date").

As of the Expiration Date, MQ Associates had received tenders and consents for $132,455,000 in aggregate principal amount of the Notes, representing 97.9550% of the outstanding Notes.

As previously announced, the total consideration (the "Total Consideration") per $1,000 principal amount at maturity of Notes that were validly tendered prior to 5:00 p.m., New York City time, on January 14, 2008 (the "Consent Date") will be an amount equal to 110.081% of the accreted value of such Notes as of the later of January 29, 2008 or the applicable payment date, which includes a cash consent payment of $28.12. Holders who tendered their Notes and delivered their consents after the Consent Date, but prior to the Expiration Date, will receive the tender offer consideration, which consists of the Total Consideration less the cash consent payment of $28.12 per $1,000 principal amount at maturity of tendered Notes. MQ Associates intends for the payment date for all Notes validly tendered to be January 30, 2008, in which case the Total Consideration will be $1,032.27 for each $1,000 principal amount at maturity of such Notes.

The complete terms and conditions of the tender offer and consent solicitation are described in the Offer to Purchase and Consent Solicitation Statement of MQ Associates, dated December 31, 2007 (the "Statement") and the related Consent and Letter of Transmittal, copies of which may be obtained by contacting D.F. King & Co., Inc., the Information Agent for the tender offer and consent solicitation, at (212) 269-5550 (for brokers and banks) or (800) 859-8509 (for all others). Questions regarding the tender offer and consent solicitation may be directed to the Dealer Manager and Solicitation Agent for the tender offer and consent solicitation: Jefferies & Company, Inc, which may be contacted at (888) 708-5831 (toll-free).

The tender offer and consent solicitation are being made only through and subject to the terms and conditions set forth in the Statement and the related Consent and Letter of Transmittal.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offering, solicitation or sale would be unlawful. Under no circumstances shall this press release constitute a solicitation of consents to the Amendment. No recommendation is made as to whether holders of the Notes should give their consent.

Forward Looking Statements

This press release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, statements regarding MQ Associates' future growth and profitability, growth strategy and trends in the industry in which it operates. These forward-looking statements are based on MQ Associates' current expectations and are subject to a number of risks, uncertainties and assumptions. MQ Associates can give no assurance that such forward-looking statements will prove to be correct. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are the recently closed merger with Novant, general economic and business conditions, the effect of healthcare industry trends on third-party reimbursement rates and demand for its services, limitations and delays in reimbursement by third- party payors, changes in governmental regulations that affect its ability to do business, actions of its competitors, introduction of new technologies, risks associated with its acquisition strategy and integration costs, and the additional factors and risks contained in MQ Associates' Annual Report on Form 10-K for the year ended December 31, 2006, as well as its other periodic reports filed with the SEC. MQ Associates undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as otherwise required by law.

MedQuest is a leading operator of independent, fixed-site, outpatient diagnostic imaging centers in the United States. MedQuest centers provide high quality diagnostic imaging services using a variety of technologies including magnetic resonance imaging (MRI), computed tomography (CT), nuclear medicine, general radiology, bone densitometry, ultrasound and mammography. MedQuest operates a network of 92 centers in 13 states located primarily throughout the southeastern and southwestern United States.


'/>"/>
SOURCE MQ Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MHA Announces: Managed Health Care Associates, Inc. (MHA) Expands Board of Directors
2. MQ Associates, Inc. Announces Cash Tender Offer for 121/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Related Consent Solicitation
3. Shareholder Class Action Filed Against Health Management Associates, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
4. MQ Associates, Inc. Announces Expiration of its Tender Offers for its 12 1/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Medquest, Inc.s 11 7/8% Senior Subordinated Notes Due 2012 (CUSIP No. 58505DAD1)
5. National HealthCare Recognized for Outstanding Sales Leadership by Long Term Care Associates, Inc.
6. MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007
7. Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Hanger Orthopedic Group, Inc. Announces Senior Leadership Succession Plan and Reaffirms Guidance
10. Webcast Alert: HCA Announces 4Q-Year End 07 Earnings Report
11. Pennsylvania Governor Rendell Announces $1.8 Million Investment to Add Nurses, Improve Nurse Education Grants Awarded to Recipients in 28 Counties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may ... pelvic conditions and has helped many women become pregnant upon treating their diagnosis. ... office-based and simple outpatient evaluations. We can provide the necessary information to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant ... produce more and better food, with fewer resources. It highlights the business’ principles, ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... proud to announce that it has received 510(k) clearance from the U.S. Food ... and the MyoCycle Pro. , Both devices are stationary cycling systems that use ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges the ... how his administration could impact the employee benefits industry. James Slotnick, AVP, Government ... likely to make it through Congress. His discussion will focus on the current ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  CVS Pharmacy, the retail division of CVS ... design to enhance the retail customer experience with ... and expanded beauty selections paired with informational signage ... offerings. Together with its innovative digital programs, these ... experience at CVS Pharmacy.  "Pharmacy ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology: